Filing summary
Important issuer mismatch: The supplied filing is Avista Healthcare Public Acquisition Corp.’s Form 10-Q for the quarter ended March 31, 2017—not an Organogenesis Holdings Inc. filing. It describes a blank-check company seeking a business combination, not an operating healthcare business.
Business context and reporting period
Avista was a Cayman Islands SPAC and reported that it had not commenced operations. Its activities were formation, public-offering-related matters, and identifying and evaluating potential acquisition targets. The company said it was considering opportunities but could not determine whether it would complete a business combination with any target. The filing was signed May 12, 2017.
Financial and operating metrics
| Metric | Q1 2017 / March 31, 2017 | Comparable period / December 31, 2016 |
|---|---|---|
| Operating revenue | None; the company said it would not generate operating revenue until after a business combination, at the earliest. | None reported. |
| Operating costs | $218,648 | $15,550 in Q1 2016 |
| Net income (loss) | $140,863 | $(15,550) in Q1 2016 |
| Interest income | $359,511 | $0 in Q1 2016 |
| Cash and cash equivalents outside trust | $486,200 | $1,040,068 |
| Cash reported as available for working capital in MD&A | $345,377 | Not stated as a comparable figure |
| Trust account | $310,359,511, including $359,511 accrued interest | $310,000,000 at December 31, 2016 |
| Current liabilities | $140,823 | $478,360 |
| Deferred underwriting commission | $10,850,000 | $10,850,000 |
Basic and diluted earnings per share were $0.02, versus a loss per share of $0.00 (rounded) in Q1 2016. The Q1 2017 trust investment earned an effective annualized rate of 0.508%. Net cash used in operating activities was $126,290, and net cash used in financing activities was $427,578, primarily reflecting payment of offering costs. The filing reports no long-term debt, lease obligations, or off-balance-sheet arrangements. It does not provide an operating-business margin measure.
Material changes versus the prior comparable period
- Net income improved to $140,863 from a $15,550 loss, primarily because trust-account interest income began in 2017; operating costs rose to $218,648 from $15,550.
- Cash outside the trust declined by $553,868 during the quarter, while the trust balance increased by accrued interest.
- The company said there had been no significant change in its financial or trading position and no material adverse change since the financial statements.
Outlook, risks, and unusual items
- Management said it believed available funds were sufficient to pursue a business combination by October 14, 2018, the 24-month deadline, and did not expect to need additional funds over the next 12 months. It cautioned that actual target-search and transaction costs could exceed estimates; sponsor or affiliate loans were possible but not committed.
- As of April 30, 2017, an affiliate agreed to defer the $10,000 monthly administrative fee until a business combination. Accrued deferred fees would then be payable.
- If no business combination is completed by October 14, 2018, the company must cease operations, redeem public shares from the trust (subject to stated deductions and legal requirements), and liquidate. Public-share redemptions and transaction financing needs could affect funds available for a transaction.
- The filing notes that third-party claims could reduce trust funds and that the sponsor’s ability to satisfy its indemnity obligation had not been independently verified; the sponsor might lack sufficient resources.
- The $10.85 million deferred underwriting commission is payable upon a completed business combination and is forfeited if the company fails to complete one, subject to the underwriting agreement.
- No new or changed risk factors were reported relative to the 2016 Form 10-K. Management reported disclosure controls were effective and no material change in internal control during the quarter. No legal proceedings were reported.
Important facts for investors to verify
- Confirm issuer identity: this filing is for Avista Healthcare Public Acquisition Corp., not Organogenesis Holdings Inc.
- Verify the reported working-capital availability of $345,377 against the balance-sheet cash of $486,200 and the company’s near-term expenses and obligations.
- Check subsequent filings for any identified target, signed transaction agreement, financing, or change to the October 14, 2018 deadline.
- Assess public-share redemption levels, deferred underwriting fees, potential sponsor support, and the risks to trust assets from claims.